3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Neoplasm Metastasis
3
Philadelphia Chromosome
2
Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia
2
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Blast Crisis
1
Interventions
Cyclophosphamide
25
fludarabine
19
Dexamethasone
17
pembrolizumab
13
Rituximab
12
venetoclax
9
Lenalidomide
9
Gemcitabine
9
Etoposide
9
pomalidomide
8
Vincristine
7
glofitamab
6
fludarabine phosphate
6
carfilzomib
6
Temozolomide
6
obinutuzumab
5
daratumumab
5
Prednisone
5
Nivolumab
5
Doxorubicin
5
Cisplatin
5
Calcium Dobesilate
5
Bortezomib
5
zanubrutinib
4
selinexor
4
Immunotherapy, Adoptive
4
Cytarabine
4
Carboplatin
4
Azacitidine
4
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
nilotinib
×
90 days
×
Clear all
NCT01774630
2026-05-26
NiloPost-STIM
University Hospital, Bordeaux
Phase 2
Completed
31 enrolled